Alligator Bioscience AB: Interim report January–March 2021


High activity during the first quarter

”So far, 2021 has been characterized by high activity, with a research collaboration that validates our Discovery concept, and good progress of our clinical programs, with ATOR-1017 and mitazalimab entering clinical efficacy studies this year.”

Malin Carlsson, Interim CEO Alligator Bioscience AB

Alligator Bioscience publishes Annual Report for 2020


Lund, Sweden, March 18, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2020 has been published. The Annual Report is attached as a PDF and is available on the company’s website,  For further information, please contact: Per Norlén, CEO E-mail: Phone: +46 46 540 82 00 Marie Svensson, […]

Alligator Bioscience AB: Year-end Report January-December 2020


Continued focus on clinical development. “Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with metastatic cancer. The results show a promising safety profile with only minor drug-related side effects.”  Per Norlén, CEO Alligator Bioscience    SIGNIFICANT EVENTS OCTOBER-DECEMBER Mitazalimab: •    New preclinical comparative data showed that mitazalimab has […]

Alligator Bioscience AB (publ): Interim report January-September 2020


Encouraging clinical safety data for ATOR-1017

The Phase I study with ATOR-1017 has progressed exceptionally well and in August we presented interim data that showed a good safety profile at clinically relevant dose levels. The dose evaluation will continue with yet higher doses and we expect to present safety and potentially efficacy data from the entire study in the spring of 2021. At the same time, we have shown strong Proof of Mechanism data for mitazalimab, while the ATOR-1015 program reported side effects at high dose levels.The nature of the reactions have lead to a need to re-design the planned clinical trial in malignant melanoma and to perform additional preclinical investigations. We will now focus our clinical investments to ATOR-1017 and mitazalimab. Both programs have first-in-class potential, and will move into clinical Phase II during 2021″, commented CEO Per Norlén.

Alligator Bioscience AB (publ) Interim report January-June 2020


Promising safety data for ATOR-1015
“With the new strategy announced in early April, we have put a stronger focus on Alligator’s clinical development portfolio. ATOR-1015 has received a great deal of attention in connection with the positive interim data presented at AACR and ASCO, the world’s two largest oncology conferences. We have also worked actively with business development and signed a research agreement with Scandion Oncology during the period, while our collaboration with Biotheus developed well and led to an additional milestone payment. The Covid-19 pandemic has been stressful but has not led to any serious delays in the clinical projects. We are now looking forward to an exciting second half of 2020 for Alligator”, commented CEO Per Norlén.

Alligator Bioscience AB (publ) Interim report January-March 2020


Stronger focus on clinical projects “The focusing of our operations protects the company’s liquidity, but is also part of our long-term strategy with a emphasis on clinical projects and innovation,” CEO Per Norlén comments. Significant events January-March • Andreas Johannesson was appointed interim CFO. • The COVID-19 pandemic impacts the recruitment of new patients to […]

Alligator Bioscience’s Annual Report 2019 published


Lund, Sweden, 2 March 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, announced today that the Swedish version of the Annual Report 2019 is available on the company website An English version will follow shortly. For further information, please contact: Cecilia Hofvander, Director Investor Relations & […]

Alligator Bioscience AB Interim report January-September 2019


“We are now regaining the exclusive, global rights to develop and commercialize ADC-1013 and at the same time receive enough ADC-1013 substance to, with or without a new partner, bring ADC-1013 into Phase II clinical trials next year. In total, we now have three projects in clinical development, and soon another one where the first […]